



## United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/714,409	11/14/2000	Leisa Johnson	ONYX1033ord	5051
7:	590 01/29/2002		,	
Gregory Giotta			EXAMINER	
ONYX Pharma 3031 Research	Drive	NGUYEN, DAVE TRONG		
Richmond, CA	94806		ART UNIT	PAPER NUMBER
			1633	
			DATE MAILED: 01/29/2002	: 1

Please find below and/or attached an Office communication concerning this application or proceeding.



## UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/714,409	11/14/2000	Johnson  DAVE NGUYEN	EXAMINER
		ART UNIT 1632 7	PAPER NUMBER

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application.

## Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

Applicant is given ONE MONTH from the mailing date of this communication within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Any inquiry concerning this communication or earlier communications regarding the formalities should be directed to Patent Analyst Dianiece Jacobs, whose telephone number is (703) 305-3388.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to examiner *Dave Nguyen* whose telephone number is

(703) 305-2024.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, *Deborah Clark*, may be reached at **(703) 305-4051**.

Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center number is (703) 305-7401.

Any inquiry of a general nature or relating to the status of this application should be directed to the *Group receptionist* whose telephone number is **(703) 308-0196**.

Dave Nguyen Primary Examiner Art Unit: 1632

DAVET NGUYEN PRIMARY EXAMINER

Application	No.:_	09/714,409
-------------	-------	------------

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

9 .	2001(0).	
X	. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. At attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).	), and 1114
X	2. This application does not contain, as a separate part of the disclosure on paper copy, a "S Listing" as required by 37 C.F.R. 1.821(c).	Sequence
X	<ol> <li>A copy of the "Sequence Listing" in computer readable form has not been submitted as re 37 C.F.R. 1.821(e).</li> </ol>	equired by
	I. A copy of the "Sequence Listing" in computer readable form has been submitted. Howev content of the computer readable form does not comply with the requirements of 37 C.F.f and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing	K. 1.822
	5. The computer readable form that has been filed with this application has been found to be and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substit computer readable form must be submitted as required by 37 C.F.R. 1.825(d).	e damaged ute
	<ol> <li>The paper copy of the "Sequence Listing" is not the same as the computer readable from "Sequence Listing" as required by 37 C.F.R. 1.821(e).</li> </ol>	of the
	7. Other: _	
Ap	licant Must Provide:	
X	An <u>initial</u> or substitute computer readable form (CRF) copy of the "Sequence Listing".	
X	An <u>initial</u> or substitute paper copy of the "Sequence Listing", as well as an amendment direc into the specification.	ting its entry
X	A statement that the content of the paper and computer readable copies are the same and, applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) 1.825(b) or 1.825(d).	where or
Fo	questions regarding compliance to these requirements, please contact:	
Fo Fo	Rules Interpretation, call (703) 308-4216 CRF Submission Help, call (703) 308-4212 entIn Software Program Support Technical Assistance	
	PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY	Y